Vimarsana
Biggest News Aggregation in the World

Page 10 - Thomas Biegi News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Thomas Biegi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Thomas Biegi Today - Breaking & Trending Today

MorphoSys AG: MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability - Vimarsana News

MorphoSys AG: MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability

Preliminary 2022 Monjuvi U.S. net product sales of US$ 89.4 million ( € 84.9 million)Anticipated 2023 Monjuvi U.S. net product sales in the range of US$ 80 to 95 millionPreliminary unaudited financial

EQS-News: Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023 - Vimarsana News

EQS-News: Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023

EQS-News: MorphoSys AG / Key word(s): Miscellaneous Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023 20.12.20...

Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023 - Vimarsana News

Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023

EQS-News: MorphoSys AG / Key word(s): MiscellaneousChief Financial Officer Sung Lee to Leave MorphoSys in March 2023 20.12.2022 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, December 20, 2022 Chief Financial Officer Sung Lee to Leave...

MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIN - Vimarsana News

MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIN

EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022 10.12.2022 / 23:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media Release  PLANEGG/MUNICH, Germa...

MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potenti - Vimarsana News

MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potenti

EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022  11.12.2022 / 23:31 CET/CESTThe issuer is solely responsible for the content of this announcement.Media Release  ...